Literature DB >> 20178837

Possible involvement of toll-like receptor 4/myeloid differentiation factor-2 activity of opioid inactive isomers causes spinal proinflammation and related behavioral consequences.

M R Hutchinson1, S S Lewis, B D Coats, N Rezvani, Y Zhang, J L Wieseler, A A Somogyi, H Yin, S F Maier, K C Rice, L R Watkins.   

Abstract

Opioid-induced glial activation and its proinflammatory consequences have been associated with both reduced acute opioid analgesia and the enhanced development of tolerance, hyperalgesia and allodynia following chronic opioid administration. Intriguingly, recent evidence demonstrates that these effects can result independently from the activation of classical, stereoselective opioid receptors. Here, a structurally disparate range of opioids cause activation of signaling by the innate immune receptor toll like receptor 4 (TLR4), resulting in proinflammatory glial activation. In the present series of studies, we demonstrate that the (+)-isomers of methadone and morphine, which bind with negligible affinity to classical opioid receptors, induced upregulation of proinflammatory cytokine and chemokine production in rat isolated dorsal spinal cord. Chronic intrathecal (+)-methadone produced hyperalgesia and allodynia, which were associated with significantly increased spinal glial activation (TLR4 mRNA and protein) and the expression of multiple chemokines and cytokines. Statistical analysis suggests that a cluster of cytokines and chemokines may contribute to these nociceptive behavioral changes. Acute intrathecal (+)-methadone and (+)-morphine were also found to induce microglial, interleukin-1 and TLR4/myeloid differentiation factor-2 (MD-2) dependent enhancement of pain responsivity. In silico docking analysis demonstrated (+)-naloxone sensitive docking of (+)-methadone and (+)-morphine to human MD-2. Collectively, these data provide the first evidence of the pro-nociceptive consequences of small molecule xenobiotic activation of spinal TLR4 signaling independent of classical opioid receptor involvement. Copyright 2010 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20178837      PMCID: PMC2854318          DOI: 10.1016/j.neuroscience.2010.02.011

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  40 in total

1.  The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations.

Authors:  R M Baron; D A Kenny
Journal:  J Pers Soc Psychol       Date:  1986-12

2.  A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia.

Authors:  K Hargreaves; R Dubner; F Brown; C Flores; J Joris
Journal:  Pain       Date:  1988-01       Impact factor: 6.961

3.  Priming effect of morphine on the production of tumor necrosis factor-alpha by microglia: implications in respiratory burst activity and human immunodeficiency virus-1 expression.

Authors:  C C Chao; G Gekker; W S Sheng; S Hu; M Tsang; P K Peterson
Journal:  J Pharmacol Exp Ther       Date:  1994-04       Impact factor: 4.030

4.  Thermal hyperalgesia and mechanical allodynia produced by intrathecal administration of the human immunodeficiency virus-1 (HIV-1) envelope glycoprotein, gp120.

Authors:  E D Milligan; K K Mehmert; J L Hinde; L O Harvey; D Martin; K J Tracey; S F Maier; L R Watkins
Journal:  Brain Res       Date:  2000-04-07       Impact factor: 3.252

5.  Suggestive evidence for receptors for morphine and methionine-enkephalin on normal human blood T lymphocytes.

Authors:  J Wybran; T Appelboom; J P Famaey; A Govaerts
Journal:  J Immunol       Date:  1979-09       Impact factor: 5.422

6.  A role for proinflammatory cytokines and fractalkine in analgesia, tolerance, and subsequent pain facilitation induced by chronic intrathecal morphine.

Authors:  Ian N Johnston; Erin D Milligan; Julie Wieseler-Frank; Matthew G Frank; Varlin Zapata; Jay Campisi; Stephen Langer; David Martin; Paula Green; M Fleshner; Leslie Leinwand; Steven F Maier; Linda R Watkins
Journal:  J Neurosci       Date:  2004-08-18       Impact factor: 6.167

7.  Stereospecific and nonstereospecific effects of (+)- and (-)-morphine: evidence for a new class of receptors?

Authors:  Y F Jacquet; W A Klee; K C Rice; I Iijima; J Minamikawa
Journal:  Science       Date:  1977-11-25       Impact factor: 47.728

8.  Quantitative real-time RT-PCR assessment of spinal microglial and astrocytic activation markers in a rat model of neuropathic pain.

Authors:  F Y Tanga; V Raghavendra; J A DeLeo
Journal:  Neurochem Int       Date:  2004 Jul-Aug       Impact factor: 3.921

9.  Quantitative assessment of tactile allodynia in the rat paw.

Authors:  S R Chaplan; F W Bach; J W Pogrel; J M Chung; T L Yaksh
Journal:  J Neurosci Methods       Date:  1994-07       Impact factor: 2.390

10.  Complete Freunds adjuvant-induced peripheral inflammation evokes glial activation and proinflammatory cytokine expression in the CNS.

Authors:  Vasudeva Raghavendra; Flobert Y Tanga; Joyce A DeLeo
Journal:  Eur J Neurosci       Date:  2004-07       Impact factor: 3.386

View more
  62 in total

1.  CXCR4 signaling mediates morphine-induced tactile hyperalgesia.

Authors:  Natalie M Wilson; Hosung Jung; Matthew S Ripsch; Richard J Miller; Fletcher A White
Journal:  Brain Behav Immun       Date:  2010-12-28       Impact factor: 7.217

2.  Inhibiting the TLR4-MyD88 signalling cascade by genetic or pharmacological strategies reduces acute alcohol-induced sedation and motor impairment in mice.

Authors:  Yue Wu; Erin L Lousberg; Lachlan M Moldenhauer; John D Hayball; Janet K Coller; Kenner C Rice; Linda R Watkins; Andrew A Somogyi; Mark R Hutchinson
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 3.  Toll-like receptors in chronic pain.

Authors:  Lauren Nicotra; Lisa C Loram; Linda R Watkins; Mark R Hutchinson
Journal:  Exp Neurol       Date:  2011-10-06       Impact factor: 5.330

Review 4.  Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia.

Authors:  Mark R Hutchinson; Yehuda Shavit; Peter M Grace; Kenner C Rice; Steven F Maier; Linda R Watkins
Journal:  Pharmacol Rev       Date:  2011-07-13       Impact factor: 25.468

5.  Role of phosphodiesterase inhibitor Ibudilast in morphine-induced hippocampal injury.

Authors:  Mohsen Zhaleh; Marzieh Panahi; Mehri Ghafurian Broujerdnia; Rostam Ghorbani; Kambiz Ahmadi Angali; Ghasem Saki
Journal:  J Inj Violence Res       Date:  2013-10-11

6.  Chronic morphine-mediated upregulation of high mobility group box 1 in the spinal cord contributes to analgesic tolerance and hyperalgesia in rats.

Authors:  Junliang Qian; Yanan Zhu; Liying Bai; Yan Gao; Mingjun Jiang; Fei Xing; Jian Zhang; Wenchao Zhao; Hanwen Gu; Yang Mi; Yuan-Xiang Tao; Ji-Tian Xu
Journal:  Neurotherapeutics       Date:  2020-04       Impact factor: 7.620

7.  Prophylactic treatment with the tricyclic antidepressant desipramine prevents development of paclitaxel-induced neuropathic pain through activation of endogenous analgesic systems.

Authors:  Liting Deng; Wan-Hung Lee; Zhili Xu; Alexandros Makriyannis; Andrea G Hohmann
Journal:  Pharmacol Res       Date:  2016-10-20       Impact factor: 7.658

Review 8.  Neurogenic neuroinflammation: inflammatory CNS reactions in response to neuronal activity.

Authors:  Dimitris N Xanthos; Jürgen Sandkühler
Journal:  Nat Rev Neurosci       Date:  2013-11-27       Impact factor: 34.870

9.  Prior exposure to repeated morphine potentiates mechanical allodynia induced by peripheral inflammation and neuropathy.

Authors:  Lisa C Loram; Peter M Grace; Keith A Strand; Frederick R Taylor; Amanda Ellis; Debra Berkelhammer; Melissa Bowlin; Bryce Skarda; Steven F Maier; Linda R Watkins
Journal:  Brain Behav Immun       Date:  2012-08-10       Impact factor: 7.217

10.  Role of meningeal mast cells in intrathecal morphine-evoked granuloma formation.

Authors:  Tony L Yaksh; Jeffery W Allen; Samantha L Veesart; Kjersti A Horais; Shelle A Malkmus; Miriam Scadeng; Joanne J Steinauer; Steve S Rossi
Journal:  Anesthesiology       Date:  2013-03       Impact factor: 7.892

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.